Key result
A novel gradient RP-HPLC method was successfully developed and validated for the quantification of a new impurity, IMP-20.15/2.57, in rivaroxaban API, which was found to be non-mutagenic in silico.
Why the study?
Evaluating the quality and impurities of rivaroxaban is required for safety and efficacy following the discovery of a new impurity during intermediate production.
A novel RP-HPLC method was developed and validated for the quantification of a newly identified impurity in rivaroxaban, ensuring drug quality and safety.
Answers are grounded in this paper and cite their sources.
Requires enhanced impurity monitoring in rivaroxaban production; leaves open clinical relevance of IMP-20.15/2.57.
Background For rivaroxaban (RRBN) to be safe and effective, its quality and impurities need to be evaluated. One new impurity (IMP-20.15/2.57) was found during the analysis of intermediate stage compound of RRBN production. The isolation of IMP-20.15/2.57 was achieved by preparative HPLC, using 10 mM ammonium acetate and acetonitrile (gradient elution mode) as mobile phase. The IMP-20.15/2.57 was elucidated using mass spectrometer, FT-IR and NMR ( 1 H and 13 C) techniques. A gradient RP-HPLC method was developed for IMP-20.15/2.57 quantification in RRBN API. The chromatographic separation of IMP-20.15/2.57 was done on a Zorbax Eclipse XDB [C18 3.0 mm × 15 cm, 3.5 µm] column with UV detection programmed at 250 nm. Solution A (methanol and buffer have been blended in a 05:95 v/v ratio) and Solution B (acetonitrile) make up the gradient mobile phase. The three batches of RRBN API were analyzed with the developed gradient RP-HPLC approach for the content of IMP-20.15/2.57. Risk assessment tests for IMP-20.15/2.57 were conducted utilizing in silico programs. Results The IMP-20.15/2.57 was elucidated as 4-(4-(2-hydroxy-3-(2-hydroxy-3-(4-(3-oxomorpholino) phenyl amino) propyl amino) propyl amino) phenyl) morpholin-3-one using mass spectrometer, FT-IR and NMR ( 1 H and 13 C) techniques. The novel approach was evaluated in accordance with ICH requirements for linearity (0.2495–1.4971 µg/mL; R 2 -0.99958), accuracy (109.97–117.71% recovery), precision (0.6015–0.9211%RSD), specificity (996.5 peak purity), robustness (no significant variation in retention time and resolution), and quantification limitations (0.2495 µg/mL). The results were deemed appropriate. It became apparent that the IMP-20.15/2.57 content in three batches of RRBN API were below the quantification limits. The in-silico program suggested that there was certainly no possibility of mutagenicity with IMP-20.15/2.57. Conclusion The present gradient RP-HPLC approach suits best for the IMP-20.15/2.57 quantification in RRBN API and offers more effective ways to guarantee the safety of patients and the quality of RRBN.
No takes yet. Share an insight, caveat, or question.
Epuru et al. (2025) studied this question. Gradient RP-HPLC method was evaluated on Quantification and characterization of IMP-20.15/2.57 in RRBN API. A novel gradient RP-HPLC method was successfully developed and validated for the quantification of a new impurity, IMP-20.15/2.57, in rivaroxaban API, which was found to be non-mutagenic in silico.
Synapse has enriched 10 related papers. Consider them for comparative context: